170 related articles for article (PubMed ID: 23670891)
1. Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors.
Pathi S; Li X; Safe S
Mol Carcinog; 2014 Feb; 53 Suppl 1():E53-61. PubMed ID: 23670891
[TBL] [Abstract][Full Text] [Related]
2. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors.
Chintharlapalli S; Papineni S; Lei P; Pathi S; Safe S
BMC Cancer; 2011 Aug; 11():371. PubMed ID: 21864401
[TBL] [Abstract][Full Text] [Related]
3. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.
Sankpal UT; Abdelrahim M; Connelly SF; Lee CM; Madero-Visbal R; Colon J; Smith J; Safe S; Maliakal P; Basha R
Prostate; 2012 Nov; 72(15):1648-58. PubMed ID: 22473873
[TBL] [Abstract][Full Text] [Related]
4. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice.
Colon J; Basha MR; Madero-Visbal R; Konduri S; Baker CH; Herrera LJ; Safe S; Sheikh-Hamad D; Abudayyeh A; Alvarado B; Abdelrahim M
Invest New Drugs; 2011 Feb; 29(1):41-51. PubMed ID: 19851711
[TBL] [Abstract][Full Text] [Related]
5. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
Abdelrahim M; Baker CH; Abbruzzese JL; Safe S
J Natl Cancer Inst; 2006 Jun; 98(12):855-68. PubMed ID: 16788159
[TBL] [Abstract][Full Text] [Related]
6. GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway.
Pathi SS; Jutooru I; Chadalapaka G; Sreevalsan S; Anand S; Thatcher GR; Safe S
Mol Cancer Res; 2011 Feb; 9(2):195-202. PubMed ID: 21156786
[TBL] [Abstract][Full Text] [Related]
7. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met.
Papineni S; Chintharlapalli S; Abdelrahim M; Lee SO; Burghardt R; Abudayyeh A; Baker C; Herrera L; Safe S
Carcinogenesis; 2009 Jul; 30(7):1193-201. PubMed ID: 19406933
[TBL] [Abstract][Full Text] [Related]
8. Sulindac sulfide inhibits colon cancer cell growth and downregulates specificity protein transcription factors.
Li X; Pathi SS; Safe S
BMC Cancer; 2015 Dec; 15():974. PubMed ID: 26673922
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.
Chadalapaka G; Jutooru I; Sreevalsan S; Pathi S; Kim K; Chen C; Crose L; Linardic C; Safe S
Int J Cancer; 2013 Feb; 132(4):795-806. PubMed ID: 22815231
[TBL] [Abstract][Full Text] [Related]
10. Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs.
Gandhy SU; Kim K; Larsen L; Rosengren RJ; Safe S
BMC Cancer; 2012 Nov; 12():564. PubMed ID: 23194063
[TBL] [Abstract][Full Text] [Related]
11. Aspirin inhibits colon cancer cell and tumor growth and downregulates specificity protein (Sp) transcription factors.
Pathi S; Jutooru I; Chadalapaka G; Nair V; Lee SO; Safe S
PLoS One; 2012; 7(10):e48208. PubMed ID: 23110215
[TBL] [Abstract][Full Text] [Related]
12. Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1.
Choi ES; Shim JH; Jung JY; Kim HJ; Choi KH; Shin JA; Nam JS; Cho NP; Cho SD
Cancer Sci; 2011 Apr; 102(4):742-8. PubMed ID: 21241418
[TBL] [Abstract][Full Text] [Related]
13. Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma.
Eslin D; Sankpal UT; Lee C; Sutphin RM; Maliakal P; Currier E; Sholler G; Khan M; Basha R
Mol Carcinog; 2013 May; 52(5):377-86. PubMed ID: 22213339
[TBL] [Abstract][Full Text] [Related]
14. Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study.
Eslin D; Lee C; Sankpal UT; Maliakal P; Sutphin RM; Abraham L; Basha R
Tumour Biol; 2013 Oct; 34(5):2781-9. PubMed ID: 23686785
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon cancer cells.
Chintharlapalli S; Papineni S; Abdelrahim M; Abudayyeh A; Jutooru I; Chadalapaka G; Wu F; Mertens-Talcott S; Vanderlaag K; Cho SD; Smith R; Safe S
Int J Cancer; 2009 Oct; 125(8):1965-74. PubMed ID: 19582879
[TBL] [Abstract][Full Text] [Related]
16. The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression.
Liu X; Abdelrahim M; Abudayyeh A; Lei P; Safe S
Mol Cancer Ther; 2009 May; 8(5):1207-17. PubMed ID: 19435870
[TBL] [Abstract][Full Text] [Related]
17. Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors.
Hurtado M; Sankpal UT; Kaba A; Mahammad S; Chhabra J; Brown DT; Gurung RK; Holder AA; Vishwanatha JK; Basha R
Cell Physiol Biochem; 2018; 51(4):1894-1907. PubMed ID: 30504717
[TBL] [Abstract][Full Text] [Related]
18. Tolfenamic acid downregulates β-catenin in colon cancer.
Ha T; Lou Z; Baek SJ; Lee SH
Int Immunopharmacol; 2016 Jun; 35():287-293. PubMed ID: 27089389
[TBL] [Abstract][Full Text] [Related]
19. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors.
Basha R; Ingersoll SB; Sankpal UT; Ahmad S; Baker CH; Edwards JR; Holloway RW; Kaja S; Abdelrahim M
Gynecol Oncol; 2011 Jul; 122(1):163-70. PubMed ID: 21496890
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation.
Jutooru I; Chadalapaka G; Lei P; Safe S
J Biol Chem; 2010 Aug; 285(33):25332-44. PubMed ID: 20538607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
